• Overview of data to be presented at the 2023 ASCO Annual Meeting to be included in the update
  
• Live webcast to be held on Tuesday, June 6^th at 8:00 a.m. ET

NEW YORK and SAN DIEGO, May 23, 2023 (GLOBE NEWSWIRE) -- Zentalis^® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that the Company will host an investor update call to share the safety and efficacy results from its ongoing monotherapy dose optimization Phase 1 study of azenosertib, its potentially first-in-class WEE1 inhibitor product candidate. The Company will also recap data that will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting and provide an overview of future clinical development plans for azenosertib.

Kimberly Blackwell, M.D., Chief Executive Officer of Zentalis, and Carrie Brownstein, M.D., Chief Medical Officer of Zentalis, will be joined on the webcast by Funda Meric-Bernstam, M.D., Chair of the Department of Investigational Cancer Therapeutics – the Phase 1 Program at The University of Texas MD Anderson Cancer Center and a member of Zentalis’ Scientific Advisory Board.

“We look forward to sharing the results of our dose optimization work for azenosertib as we advance this promising WEE1 inhibitor to patients,” said Dr. Blackwell. “This work has allowed for further interrogation of the full potential of WEE1 inhibition in certain tumor types, and I am excited to share the results and our plans to advance azenosertib in the clinic.”

The webcast will be at 8:00 a.m. ET on Tuesday, June 6, 2023 and will be accessible via the Investors page of Zentalis’ website, www.zentalis.com. The archived webcast and presentation will be available on the Company’s website after the event.

About Zentalis Pharmaceuticals

Zentalis^® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Utilizing its Integrated Discovery Engine, the Company is developing a focused pipeline of potentially best-in-class oncology candidates, which include azenosertib (ZN-c3), a WEE1 inhibitor for advanced solid tumors, ZN-d5, a BCL-2 inhibitor for hematologic malignancies and related disorders, and a heterobifunctional degrader of BCL-xL for solid and hematological malignancies. The Company is also leveraging its extensive experience and capabilities across cancer biology and medicinal chemistry to advance its research on protein degraders. Zentalis has operations in both New York and San Diego.

For more information, please visit www.zentalis.com. Follow Zentalis on Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements the content of planned clinical updates for azenosertib and the timing thereof and the participants therefor; and the potential for azenosertib to be first-in-class. The terms “has,” “plan,” “potential,” “will,” “work” and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; our plans, including the costs thereof, of development of any diagnostic tools; the outcome of preclinical testing and early trials may not be predictive of the success of later clinical trials; failure to identify additional product candidates and develop or commercialize marketable products; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process or ongoing regulatory obligations; failure to obtain U.S. or international marketing approval; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties; effects of significant competition; the possibility of system failures or security breaches; risks relating to intellectual property; our ability to attract, retain and motivate qualified personnel, and risks relating to management transitions; significant costs as a result of operating as a public company; and the other important factors discussed under the caption “Risk Factors” in our most recently filed periodic report on Form 10-K or 10-Q and subsequent filings with the U.S. Securities and Exchange Commission (SEC) and our other filings with the SEC. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

ZENTALIS^® and its associated logos are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release.

Investor Contacts:
Adam D. Levy, PhD, MBA
This email address is being protected from spambots. You need JavaScript enabled to view it.

Alexandra Roy
Solebury Strategic Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:
Danielle Cantey
Evoke Canale
This email address is being protected from spambots. You need JavaScript enabled to view it.
(619) 826 4657